- ICH GCP
- US-Register für klinische Studien
- Klinische Studie NCT06990841
- Originalversuch
Vergleich von zwei verschiedenen Spermienverarbeitungsmethoden und deren Auswirkungen auf die Spermien -DNA -Fragmentierung und die Embryoentwicklung
Ein prospektiver Vergleich von zwei verschiedenen Spermienpräparationstechniken zur Präsentation der DNA -Fragmentierung und der Embryoentwicklung
The goal of this clinical trial is to learn if the LensHooke CA0 device lowers DNA fragmentation in sperm samples compared to a gradient/swim-up technique.
The main questions it aims to answer are:
- Does the LensHooke® CA0 device reduce DNA fragmentation compared to the gradient/swim-up technique?
- Does the LensHooke® CA0 device improve concentration, motility, and morphology compared to the gradient/swim-up technique?
- Is sibling embryo fertilization and development the same?
- Are pregnancy rates different between the 2 groups?
1 semen sample will be split between the 2 treatment techniques. Half of the partner's egg cohort will be injected via intra-cytoplasmic sperm using sperm processed by one technique and the other half of the cohort will be injected by the sperm processed by the other technique. Both methods will look at DNA fragmentation, concentration, motility, and morphology of the sperm. Both methods will be compared in the resulting embryos looking at fertilization, embryo development and pregnancy rates.
Studienübersicht
Status
Bedingungen
Intervention / Behandlung
Studientyp
Einschreibung (Geschätzt)
Phase
- Unzutreffend
Kontakte und Standorte
Studienkontakt
- Name: Richard J Kordus, PhD
- Telefonnummer: 864-455-1675
- E-Mail: rich.kordus@prismahealth.org
Studieren Sie die Kontaktsicherung
- Name: Patti Parker
- Telefonnummer: 864-455-1510
- E-Mail: patti.parker@prismahealth.org
Studienorte
-
-
South Carolina
-
Greenville, South Carolina, Vereinigte Staaten, 29605
- Rekrutierung
- Prisma Health-Upstate Fertility Center of the Caroliinas
-
Kontakt:
- Richard J Kordus, PhD
- Telefonnummer: 864-455-1675
- E-Mail: rich.kordus@prismahealth.org
-
-
Teilnahmekriterien
Zulassungskriterien
Studienberechtigtes Alter
Akzeptiert gesunde Freiwillige
Studienberechtigte Geschlechter
Beschreibung
Inclusion Criteria:
- Samples with ≥15 M/mL spermatozoa concentration
- Female partner between 18 and 34 years old.
- Minimum of 4 fertilized eggs in gradient/swim prep group and 4 fertilized eggs in the Lenshooke prep group for each patient
Exclusion Criteria:
- Samples with <15 M/mL spermatozoa concentration
- female partner >35 years old
- female patient with recurrent pregnancy loss
- female patient with diminished ovarian reserve
Studienplan
Wie ist die Studie aufgebaut?
Designdetails
- Hauptzweck: Behandlung
- Zuteilung: N / A
- Interventionsmodell: Einzelgruppenzuweisung
- Maskierung: Keine (Offenes Etikett)
Waffen und Interventionen
Teilnehmergruppe / Arm |
Intervention / Behandlung |
|---|---|
|
Experimental: Gradient/Swim-up gegen Lenshooke CA0-Gerätevergleich
|
comparison of DNA damage between the 2 interventions and subsequent embryo development and pregnancy rates |
Was misst die Studie?
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Percentage of sperm with DNA fragmentation
Zeitfenster: From enrollment until day after sample collection, approximately 1 month
|
The method is based on the Sperm Chromatin Dispersion (SCD) test (Fernández et al., J. Androl 24:59-66, 2003; Fertil Steril 84:833-842, 2005). Intact unfixed spermatozoa (fresh, frozen/unthawed, diluted or neat samples) are immersed in an inert agarose microgel on a pretreated slide. An initial acid treatment denatures DNA in those sperm cells with fragmented DNA. Following this, the lysing solution removes most of the nuclear proteins, and in the absence of massive DNA breakage produces nucleoids with large halos of spreading DNA loops, emerging from a central core. However, the nucleoids from spermatozoa with fragmented DNA either do not show a dispersion halo or the halo is minimal. Slides are stained with Wright's stain. A minimum of 300 sperm per sample will be counted. The percentage of sperm with fragmented DNA will be calculated by dividing the sperm with small and no halos (fragmented sperm) by the total number of sperm counted. |
From enrollment until day after sample collection, approximately 1 month
|
Sekundäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Concentration of sperm per mL
Zeitfenster: From enrollment until day after sample collection, approximately 1 month
|
Assessed using a sperm class analyzer - SCA (CASA system) for sperm count. Semen samples will be loaded into 20 microliter depth fixed volume slides. Slides will be placed on the Microoptics SCA machine. Videos will be captured of fields until at least 200 motile sperm are captured. Concentration will be analyzed by counting the number of sperm within each field, corrected for the depth of the chamber, and multipled by the volume of the sample. Concentrations between fields will not vary by more than 15%. |
From enrollment until day after sample collection, approximately 1 month
|
Andere Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Percentage of motile sperm
Zeitfenster: From enrollment until day after sample collection, approximately 1 month
|
Assessed using a sperm class analyzer - SCA (CASA system) for sperm motility. Semen samples will be loaded into 20 microliter depth fixed volume slides. Slides will be placed on the Microoptics SCA machine. Videos will be captured of fields until at least 200 motile sperm are captured. Motility will be calculated as the number of motile sperm counted divided by the total number of sperm counted. Types of motility will be noted according to WHO semen analysis groupings, hyperactivation, and kinetic motion parameters. |
From enrollment until day after sample collection, approximately 1 month
|
|
Percentage of Sperm with normal morphology Using Kruger Strict Criteria
Zeitfenster: From enrollment until day after sample collection, approximately 1 month
|
10 uL volumes of sperm samples will be placed on pre-stained morphology slides using methylene blue/cresyl violet stain. A minimum of 200 sperm will be counted and assessed for normal vs abnormal sperm morphology using Kruger strict criteria. Percentage of normal sperm will be assessed my dividing the number of normal sperm by the total number of sperm counted. |
From enrollment until day after sample collection, approximately 1 month
|
|
Percentage of egg fertilization
Zeitfenster: From enrollment until a week after sample collection, approximately 5 weeks
|
The number of fertilized eggs (zygotes) will be divided by the number of eggs inseminated |
From enrollment until a week after sample collection, approximately 5 weeks
|
|
Numerical score of morphokinetic embryo development
Zeitfenster: From enrollment until a week after sample collection, approximately 5 weeks
|
Embryo development will be monitored using a time-lapse incubator. A score will be generated based on when the embryos meets developmental time points. The embryo will receive 2 points for each time point it successfully completes with expected parameters. Embryos will receive 1 point for each time point it completes but outside the expected time parameters. i.e. if an embryo has the first cleavage between 23-25 hours it will receive 2 points. If it cleaves earlier than 23 hours or later than 25 hours it will receive 1 point. The total score an embryo receives will be tallied from the time of insemination until the embryo is frozen. |
From enrollment until a week after sample collection, approximately 5 weeks
|
|
Qualitative embryo grade
Zeitfenster: From enrollment until a week after sample collection, approximately 5 weeks
|
All embryos will be graded according to a 3-part grading scale at the time of cryopreservation between days 5 and 7 of culture. The embryo will be given a number score of 1-6 based on the embryo's size, size of the blastocoel fluid cavity, and whether or not it is inside, hatching out, or completely hatched out the zona. Each embryo will get a letter grade for the quality of the inner cell mass either A, B, C, or D. Each embryo will get a second letter grade for the quality of the trophectoderm A, B, C, or D. |
From enrollment until a week after sample collection, approximately 5 weeks
|
|
Percentage of patients that become pregnant and deliver a baby
Zeitfenster: From enrollment until a delivery of infant, up to 18 months
|
Calculated by the number of patients that become pregnant (assessed by the presence of a fetal heartbeat 5-6 weeks following embryo transfer) divided by the total number of embryos transferred. Live birth will be calculated by the number of patients that give birth divided by the number of embryos transferred. |
From enrollment until a delivery of infant, up to 18 months
|
Mitarbeiter und Ermittler
Sponsor
Ermittler
- Hauptermittler: Richard Kordus, PhD, Prisma Health-Upstate Fertility Center of the Carolinas
Publikationen und hilfreiche Links
Allgemeine Veröffentlichungen
- Ho CLT, Vaughan-Constable DR, Ramsay J, Jayasena C, Tharakan T, Yap T, Whiteman I, Graham N, Minhas S, Homa ST. The relationship between genitourinary microorganisms and oxidative stress, sperm DNA fragmentation and semen parameters in infertile men. Andrologia. 2022 Mar;54(2):e14322. doi: 10.1111/and.14322. Epub 2021 Nov 24.
- Amor H, Hammadeh ME, Mohd I, Jankowski PM. Impact of heavy alcohol consumption and cigarette smoking on sperm DNA integrity. Andrologia. 2022 Aug;54(7):e14434. doi: 10.1111/and.14434. Epub 2022 Apr 28.
- Cho CL, Agarwal A, Majzoub A, Esteves SC. Clinical utility of sperm DNA fragmentation testing: concise practice recommendations. Transl Androl Urol. 2017 Sep;6(Suppl 4):S366-S373. doi: 10.21037/tau.2017.07.28.
- Rex AS, Aagaard J, Fedder J. DNA fragmentation in spermatozoa: a historical review. Andrology. 2017 Jul;5(4):622-630. doi: 10.1111/andr.12381.
Studienaufzeichnungsdaten
Haupttermine studieren
Studienbeginn (Tatsächlich)
Primärer Abschluss (Geschätzt)
Studienabschluss (Geschätzt)
Studienanmeldedaten
Zuerst eingereicht
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst gepostet (Tatsächlich)
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Tatsächlich)
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Zuletzt verifiziert
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Andere Studien-ID-Nummern
- 2295231-1
Plan für individuelle Teilnehmerdaten (IPD)
Planen Sie, individuelle Teilnehmerdaten (IPD) zu teilen?
Arzneimittel- und Geräteinformationen, Studienunterlagen
Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt
Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt
Produkt, das in den USA hergestellt und aus den USA exportiert wird
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .